Agios Pharmaceuticals Scheduled to Report Q3 2026 Earnings on November 5
Agios Pharmaceuticals (AGIO) is set to release its third-quarter 2026 financial results on Thursday, November 5, prior to the market opening. The company's performance is being closely watched as analysts anticipate significant year-over-year growth in key metrics. Market consensus projects a revenue estimate of $51.6 million, representing a substantial increase of over 300% compared to the previous year. While earnings per share (EPS) are expected to remain negative at -$1.23, this figure reflects a 30.9% improvement on a year-over-year basis.
Tickers: $AGIO